NCT00839007

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Nile Therapeutics · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Conditions

• Acute Decompensated Heart Failure

Interventions

Type	Name	Description
DRUG	CD-NP	Infusion of CD-NP at one of up to 6 doses or placebo

Timeline

• Start date: 2009-06-01
• Primary completion: 2010-06-01
• Completion: 2010-07-01
• First posted: 2009-02-09
• Last updated: 2010-09-17

Locations

21 sites across 3 countries: United States, Germany, Israel